Paper Details

  1. Home
  2. Paper Details

Systemic therapy in men with metastatic castration-resistant prostate cancer:American Society of Clinical Oncology and Cancer Care Ontario clinical practice guideline.

Author: BaschEthan, BennettCharles L, CarducciMichael, ChenRonald C, DusetzinaStacie B, FrameJames N, GarrelsKristina, HotteSebastien, KattanMichael W, LoblawD Andrew, OliverThomas K, RaghavanDerek, RumbleR Bryan, SaadFred, TaplinMary-Ellen, VirgoKatherine S, Walker-DilksCindy, WilliamsJames, WinquistEric, WoottonTed

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Research Support, U.S. Gov't, Non-P.H.S.Research funding provided by US government agencies other than the Public Health Service.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Overview

For men with metastatic castration-resistant prostate cancer, abiraterone acetate/prednisone, enzalutamide, and radium-223 are recommended for improved survival and quality of life. Docetaxel/prednisone is also recommended with moderate toxicity risk.
Paper Details　
Original Abstract of the Article :
PURPOSE: To provide treatment recommendations for men with metastatic castration-resistant prostate cancer (CRPC). METHODS: The American Society of Clinical Oncology and Cancer Care Ontario convened an expert panel to develop evidence-based recommendations informed by a systematic review of the lit...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4876355/

データ提供：米国国立医学図書館（NLM）

Navigating Metastatic Castration-Resistant Prostate Cancer: A Guide for Clinicians

This study provides comprehensive treatment recommendations for men with metastatic castration-resistant prostate cancer (CRPC), a challenging and complex disease. It's like navigating a vast desert of knowledge, seeking the most effective pathways to treatment. The study, developed by the American Society of Clinical Oncology and Cancer Care Ontario, offers a detailed roadmap for clinicians, outlining evidence-based recommendations for managing this disease. The study emphasizes the importance of individualized treatment plans, considering the specific needs and characteristics of each patient.

Treatment Options for Metastatic Castration-Resistant Prostate Cancer: A Roadmap for Clinicians

The study recommends a variety of treatment options for men with metastatic CRPC, including abiraterone acetate/prednisone, enzalutamide, radium-223, docetaxel/prednisone, and sipuleucel-T. These recommendations are based on evidence-based studies that have demonstrated their effectiveness in improving survival, quality of life, and managing toxicity. The study also emphasizes the need for palliative care to address the physical, emotional, and spiritual needs of patients.

Supporting Men with Prostate Cancer: A Multifaceted Approach

This research highlights the importance of a multifaceted approach to managing metastatic CRPC, encompassing both therapeutic interventions and palliative care. By providing comprehensive support and guidance, we can empower these men to navigate the challenges of their disease and improve their overall well-being. It's like providing a camel with a well-stocked oasis, offering it the resources it needs to survive and thrive in the harsh desert environment.

Dr.Camel's Conclusion

This study provides a valuable resource for clinicians managing metastatic CRPC. The recommendations emphasize the importance of individualized treatment plans, considering the specific needs of each patient. By combining evidence-based therapies with palliative care, we can improve the lives of men with this challenging disease. It's like guiding a camel through a difficult journey, offering it the support and resources it needs to reach its destination.

Date :
  1. Date Completed 2015-02-06
  2. Date Revised 2022-04-09
Further Info :

Pubmed ID

25199761

DOI: Digital Object Identifier

PMC4876355

Related Literature

Article Analysis
・Effective treatment of prostate cancer
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.